Popular Anti-Aging Supplement NAD+ Precursors Linked to Cancer Growth: What Scientists Found in

Why Might Anti-Aging NAD+ Supplements Promote Cancer Growth?

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in every living cell, essential for energy metabolism, DNA repair, and cellular signaling. As we age, NAD+ levels naturally decline, which has driven enormous interest in supplements that boost NAD+ — particularly nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). These compounds have been marketed aggressively as longevity aids, with animal studies showing benefits for metabolic health and age-related decline.

However, new research reported by ScienceDaily highlights a troubling trade-off: cancer cells are also highly dependent on NAD+ for their rapid growth and proliferation. By flooding the body with NAD+ precursors, individuals may be inadvertently supplying tumors with the metabolic resources they need. This concept — that the same metabolic pathways supporting healthy aging also fuel malignancy — has been a growing concern in cancer biology research. Scientists have previously shown that enzymes in the NAD+ synthesis pathway, such as NAMPT, are often overexpressed in various tumor types, suggesting cancer cells actively upregulate NAD+ production to sustain their growth.

What Does This Mean for People Currently Taking NMN or NR Supplements?

The dietary supplement industry in the United States operates under a regulatory framework that does not require pre-market approval by the FDA. This means that compounds like NMN and NR have reached millions of consumers without the rigorous, long-term safety trials required for pharmaceutical drugs. While short-term human studies have generally shown these supplements to be well-tolerated, virtually no large-scale trials have examined cancer outcomes over years of use.

Researchers emphasize that the findings do not mean NAD+ supplements directly cause cancer, but rather that in individuals who may already have undetected precancerous cells or early-stage tumors, boosting NAD+ could theoretically accelerate disease progression. This is particularly relevant for older adults — the very population most likely to take anti-aging supplements — who also carry the highest burden of undiagnosed early cancers. Scientists are calling for controlled clinical trials specifically designed to assess cancer-related endpoints in NAD+ supplement users, as well as research into whether timing, dosage, or specific formulations might mitigate the risk.

How Are Scientists Trying to Separate Anti-Aging Benefits From Cancer Risk?

One promising avenue of research involves understanding how NAD+ metabolism differs between healthy aging cells and cancer cells. While both rely on NAD+, the downstream pathways diverge significantly. Healthy cells use NAD+ primarily for mitochondrial function and DNA repair through enzymes called sirtuins and PARPs, whereas cancer cells often divert NAD+ toward glycolysis and rapid biosynthesis. Scientists are exploring whether it may be possible to boost NAD+ in ways that preferentially support healthy cellular functions without feeding tumor metabolism.

Additionally, some researchers are examining whether combining NAD+ precursors with cancer-preventive strategies — such as caloric restriction or specific dietary patterns — could offset the potential risks. The broader lesson from this research is a familiar one in medicine: interventions that seem universally beneficial in early studies often reveal more complex profiles as the science matures. For now, experts recommend that individuals considering NAD+ supplementation discuss their personal cancer risk factors with a healthcare provider, particularly those with a family history of cancer or other known risk factors.